The Pretreatment Effect of Myoinositol on Improving Egg Quality in Infertile Patients with Polycystic Ovary Syndrome

Polycystic ovary syndrome is one of the most common causes of endocrine disorders in women and the most common cause of infertility due to lack of ovulation, which affects 6-10% of women of reproductive age. The current study aimed to investigate the pretreatment effect of myoinositol on improving egg quality in infertile patients with polycystic ovary syndrome. In the current study, about 54 candidates for IVF diagnosed with polycystic ovary syndrome were included and divided into case and control groups by block randomization. The data was analyzed using descriptive and analytical statistics in the Strata software. The significance level was considered at p<0.05. The average number of administrations of CETROTIDE and rFSH as well as the number of immature eggs of the MI-GV stage, were lower in the case group compared to the control group. The positive healing effects of myoinositol on the reduction of the number and dosage of the medicines used to treat women with polycystic ovary syndrome have made it a good alternative to treat patients with this syndrome.